Published in Nat Rev Neurol on February 01, 2010
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (2010) 1.89
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer. J Transl Med (2013) 1.67
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42
Distinct cerebral perfusion patterns in FTLD and AD. Neurology (2010) 1.38
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One (2013) 1.21
Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab (2013) 1.21
Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging (2012) 1.18
Deep learning-based feature representation for AD/MCI classification. Med Image Comput Comput Assist Interv (2013) 1.18
Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One (2012) 1.18
Latent feature representation with stacked auto-encoder for AD/MCI diagnosis. Brain Struct Funct (2013) 1.16
Oxidative insults to neurons and synapse are prevented by aged garlic extract and S-allyl-L-cysteine treatment in the neuronal culture and APP-Tg mouse model. J Neurochem (2011) 1.15
Hierarchical feature representation and multimodal fusion with deep learning for AD/MCI diagnosis. Neuroimage (2014) 1.13
Radioluminescence microscopy: measuring the heterogeneous uptake of radiotracers in single living cells. PLoS One (2012) 1.06
Perspectives on episodic-like and episodic memory. Front Behav Neurosci (2013) 1.00
Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage (2011) 0.98
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology (2012) 0.95
Β-amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. PLoS One (2010) 0.94
Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. J Am Chem Soc (2013) 0.92
In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci (2016) 0.87
Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.86
Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels. PLoS One (2013) 0.86
Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimers Dement (Amst) (2015) 0.86
Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur J Nucl Med Mol Imaging (2014) 0.86
Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography. PLoS One (2015) 0.85
The emerging agenda of stratified medicine in neurology. Nat Rev Neurol (2013) 0.85
Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. J Alzheimers Dis (2015) 0.84
Subclass-based multi-task learning for Alzheimer's disease diagnosis. Front Aging Neurosci (2014) 0.84
Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. Neurobiol Aging (2013) 0.84
Cortical hypermetabolism in MCI subjects: a compensatory mechanism? Eur J Nucl Med Mol Imaging (2014) 0.83
Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. Proc Natl Acad Sci U S A (2015) 0.83
A Robust Deep Model for Improved Classification of AD/MCI Patients. IEEE J Biomed Health Inform (2015) 0.83
PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev (2014) 0.82
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine (2015) 0.82
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther (2011) 0.82
Molecular interactions of Alzheimer's biomarker FDDNP with Aβ peptide. Biophys J (2012) 0.81
Radiotracers for positron emission tomography imaging. MAGMA (2012) 0.81
Near-infrared fluorescence imaging of apoptotic neuronal cell death in a live animal model of prion disease. ACS Chem Neurosci (2010) 0.81
Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. Neuroimage (2013) 0.81
Quantitative amyloid imaging using image-derived arterial input function. PLoS One (2015) 0.80
Functional MRI and neural responses in a rat model of Alzheimer's disease. Neuroimage (2013) 0.80
QSAR studies for prediction of cross-β sheet aggregate binding affinity and selectivity. Bioorg Med Chem (2012) 0.80
Characterizing Alzheimer's disease severity via resting-awake EEG amplitude modulation analysis. PLoS One (2013) 0.80
Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease. Nucl Med Biol (2010) 0.80
Molecular imaging needles: dual-modality optical coherence tomography and fluorescence imaging of labeled antibodies deep in tissue. Biomed Opt Express (2015) 0.80
Radiation dosimetry of florbetapir F 18. EJNMMI Res (2014) 0.79
Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? Alzheimers Res Ther (2010) 0.79
Discriminative Learning for Alzheimer's Disease Diagnosis via Canonical Correlation Analysis and Multimodal Fusion. Front Aging Neurosci (2016) 0.79
Advantages in functional imaging of the brain. Front Hum Neurosci (2015) 0.79
Endothelial Dysfunction and Amyloid-β-Induced Neurovascular Alterations. Cell Mol Neurobiol (2015) 0.78
Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture. Neural Regen Res (2014) 0.76
Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol (2015) 0.75
Hemodynamic effects of combined focal cerebral ischemia and amyloid protein toxicity in a rat model: a functional CT study. PLoS One (2014) 0.75
Amyloid-β plaque deposition measured using propagation-based X-ray phase contrast CT imaging. J Synchrotron Radiat (2016) 0.75
Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization. Sci Rep (2016) 0.75
27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. J Exp Med (2017) 0.75
Sparse Multi-Response Tensor Regression for Alzheimer's Disease Study With Multivariate Clinical Assessments. IEEE Trans Med Imaging (2016) 0.75
Feed-forward hierarchical model of the ventral visual stream applied to functional brain image classification. Hum Brain Mapp (2012) 0.75
Opening up the DNA methylome of dementia. Mol Psychiatry (2017) 0.75
Sugar and Alzheimer's disease: a bittersweet truth. Nat Neurosci (2015) 0.75
Joint Coupled-Feature Representation and Coupled Boosting for AD Diagnosis. Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit (2015) 0.75
Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates. J Biol Inorg Chem (2015) 0.75
Multi-Kernel Learning with Dartel Improves Combined MRI-PET Classification of Alzheimer's Disease in AIBL Data: Group and Individual Analyses. Front Hum Neurosci (2017) 0.75
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Forecasting the global burden of Alzheimer's disease. Alzheimers Dement (2007) 10.01
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 5.42
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
In-vivo measurement of activated microglia in dementia. Lancet (2001) 3.51
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia (2008) 2.58
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci U S A (2007) 2.41
Neuronal nicotinic receptors in the human brain. Prog Neurobiol (2000) 2.31
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology (2009) 2.27
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
Posterior cingulate cortex in Alzheimer's disease. Lancet (1994) 2.11
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med (2005) 2.05
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology (2009) 1.99
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology (2007) 1.95
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.89
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology (2006) 1.85
Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol (1978) 1.82
Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol (2006) 1.81
How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann Neurol (2004) 1.77
Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol (2000) 1.73
Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology (2009) 1.70
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx (2005) 1.58
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 1.55
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage (2007) 1.53
Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry (2007) 1.52
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Positron emission tomography imaging in dementia. Br J Radiol (2007) 1.42
Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol (2006) 1.41
PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 1.39
Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging (2006) 1.39
2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med (2007) 1.37
Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A (2006) 1.34
Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging (2008) 1.31
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther (2006) 1.29
Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry (2002) 1.28
[11C]PIB binding in Parkinson's disease dementia. Neuroimage (2007) 1.24
High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res (2010) 1.23
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) (2006) 1.15
Amyloid imaging in Alzheimer's disease. Curr Opin Neurol (2007) 1.14
Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med (2009) 1.14
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14
Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci (2009) 1.13
[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int (2008) 1.11
Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement (2007) 1.10
Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res (1990) 1.08
Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc Natl Acad Sci U S A (2007) 1.08
Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med (2009) 1.06
Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry (2003) 1.04
Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am J Geriatr Psychiatry (2003) 1.03
Why lipids are important for Alzheimer disease? Mol Cell Biochem (2008) 1.02
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol (2002) 1.01
Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology (2001) 1.01
Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur J Nucl Med Mol Imaging (2009) 0.97
Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol (2005) 0.97
Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2008) 0.96
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging (2009) 0.95
Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse (2003) 0.94
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 5.42
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet (2004) 2.91
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol (2008) 2.24
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab (2006) 2.02
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology (2012) 2.02
Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry (2002) 1.87
Rapid bone and blood flow formation in impacted morselized allografts: positron emission tomography (PET) studies on allografts in 5 femoral component revisions of total hip arthroplasty. Acta Orthop Scand (2003) 1.82
Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol (2003) 1.65
Binge drinking in midlife and dementia risk. Epidemiology (2005) 1.61
Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci (2005) 1.58
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging (2008) 1.55
Chronic whiplash symptoms are related to altered regional cerebral blood flow in the resting state. Eur J Pain (2008) 1.55
Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos (2008) 1.50
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci (2008) 1.47
Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett (2004) 1.47
Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse (2007) 1.46
Brain white matter expansion in human obesity and the recovering effect of dieting. J Clin Endocrinol Metab (2007) 1.46
Ventilation distribution studies comparing Technegas and "Gallgas" using 68GaCl3 as the label. J Nucl Med (2011) 1.39
GMP--three letters with many interpretations. Protection of patients or killing the clinical and research applications of PET? Eur J Nucl Med Mol Imaging (2008) 1.39
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord (2002) 1.31
Effects of working-memory training on striatal dopamine release. Science (2011) 1.30
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain (2003) 1.29
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry (2004) 1.28
18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med (2011) 1.26
Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging (2010) 1.24
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry (2005) 1.23
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med (2012) 1.19
Amygdala and anterior cingulate cortex activation during affective startle modulation: a PET study of fear. Eur J Neurosci (2003) 1.18
PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci (2004) 1.17
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage (2006) 1.17
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med (2005) 1.16
Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord (2008) 1.15
PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) (2006) 1.15
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol (2010) 1.12
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab (2006) 1.11
[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int (2008) 1.11
Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging (2014) 1.11
Altered dopamine D2 receptor binding in atypical facial pain. Pain (2003) 1.10
C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse (2009) 1.10
In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med (2012) 1.09
The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci (2002) 1.09
Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage (2012) 1.07
Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am (2003) 1.07
Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage (2002) 1.05
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse (2015) 1.05
Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord (2006) 1.05
Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev (2002) 1.04
Restricted cortical and amygdaloid removal of vesicular glutamate transporter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function. J Neurosci (2009) 1.04
Mobile phone affects cerebral blood flow in humans. J Cereb Blood Flow Metab (2006) 1.03
Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord (2004) 1.03
Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging (2005) 1.02
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol (2002) 1.01
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging (2010) 1.01
Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med (2013) 1.00
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol (2003) 0.99
Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis (2008) 0.98
Bone regeneration 6 years after impaction bone grafting: a PET analysis. Acta Orthop (2007) 0.98
Unidirectional Influx and Net Accumulation of PIB. Open Neuroimag J (2008) 0.98
Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM. BMC Med Imaging (2005) 0.98
Imaging of peptide adsorption to microfluidic channels in a plastic compact disc using a positron emitting radionuclide. Lab Chip (2005) 0.98
Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med (2007) 0.97
Cerebral blood flow and metabolism after cardiopulmonary resuscitation. A pathophysiologic and prognostic positron emission tomography pilot study. Resuscitation (2003) 0.97
Effects of a 902 MHz mobile phone on cerebral blood flow in humans: a PET study. Neuroreport (2003) 0.97
Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry (2006) 0.97
Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging (2012) 0.96
Age-related loss of extrastriatal dopamine D(2) -like receptors in women. J Neurochem (2002) 0.96
Midlife sleep characteristics associated with late life cognitive function. Sleep (2013) 0.96
Radical carbonylation with [11C]carbon monoxide promoted by oxygen-centered radicals: experimental and DFT studies of the mechanism. J Am Chem Soc (2007) 0.95
[(11)C] Carbon monoxide in selenium-mediated synthesis of (11)C-carbamoyl compounds. J Org Chem (2002) 0.95
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging (2009) 0.95
Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci (2005) 0.95
Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport (2004) 0.94
Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med (2009) 0.94
Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke (2004) 0.93
Imaging of aromatase distribution in rat and rhesus monkey brains with [11C]vorozole. Nucl Med Biol (2006) 0.93
Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging (2010) 0.93
Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord (2012) 0.92
Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging (2002) 0.92
Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging (2009) 0.92
Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr (2009) 0.91
Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci (2007) 0.90
68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med (2004) 0.90
Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis (2013) 0.90
Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.90
[(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology. Eur J Nucl Med Mol Imaging (2009) 0.90
Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction. J Neurol Sci (2013) 0.89
Expectation of caffeine induces dopaminergic responses in humans. Eur J Neurosci (2004) 0.89
Midlife alcohol consumption and later risk of cognitive impairment: a twin follow-up study. J Alzheimers Dis (2010) 0.89